ArticleCurrent atherosclerosis reports2013

When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events.

Robert S Rosenson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.